Rapid Onset of Retinal Toxicity from High-Dose Hydroxychloroquine Given for Cancer Therapy

American Journal of Ophthalmology

Volumn 160, Issue 4, 2015, Pages 799-805.e1

  Leung, Loh Shan B ^a,d   Neal, Joel W ^b   Wakelee, Heather A ^b   Sequist, Lecia V ^c   Marmor, Michael F ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERLOTINIB; HYDROXYCHLOROQUINE; ANTINEOPLASTIC AGENT; ANTIRHEUMATIC AGENT;

ADULT; ADVANCED CANCER; AGED; AMSLER CHART; ARTICLE; AUTOFLUORESCENCE; AUTOFLUORESCENCE IMAGING; CANCER CHEMOTHERAPY; CASE STUDY; CLINICAL ARTICLE; COLOR VISION TEST; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG WITHDRAWAL; ELECTRORETINOGRAPHY; EYE FUNDUS; EYE TOXICITY; FEMALE; HUMAN; HUMPHREY VISUAL FIELD TEST; LUNG ADENOCARCINOMA; MALE; MIDDLE AGED; MULTICENTER STUDY; OBSERVATIONAL STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RETINA DETACHMENT; RETINA DISEASE; RETINA EXAMINATION; RETROSPECTIVE STUDY; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; VISUAL ACUITY; VISUAL FIELD; XEROSTOMIA; CARCINOMA, NON-SMALL-CELL LUNG; CASE REPORT; CHEMICALLY INDUCED; CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; DRUG EFFECTS; FLUORESCENCE ANGIOGRAPHY; LUNG NEOPLASMS; OPTICAL COHERENCE TOMOGRAPHY; PATHOLOGY; PERIMETRY; RANDOMIZED CONTROLLED TRIAL; RETINA; RETINAL DISEASES;

AGED; ANTINEOPLASTIC AGENTS; ANTIRHEUMATIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG THERAPY, COMBINATION; ELECTRORETINOGRAPHY; ERLOTINIB HYDROCHLORIDE; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; HYDROXYCHLOROQUINE; LUNG NEOPLASMS; MALE; MIDDLE AGED; RETINA; RETINAL DISEASES; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; VISUAL FIELD TESTS; VISUAL FIELDS;

EID: 84941338642     PISSN: 00029394     EISSN: 18791891     Source Type: Journal    
DOI: 10.1016/j.ajo.2015.07.012     Document Type: Article

References (12)

1. R.B. Melles, and M.F. Marmor The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy JAMA Ophthalmol 132 12 2014 1453 1460
2. D.E. Furst, H. Lindsley, B. Baethge, and et al. Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis: a randomized, double-blind six-week trial with eighteen-week extension Arthritis Rheum 42 2 1999 357 365
3. T. Munster, J.P. Gibbs, D. Shen, and et al. Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis Arthritis Rheum 46 6 2002 1460 1469
4. M.R. Rosenfeld, X. Ye, J.G. Supko, and et al. A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme Autophagy 10 8 2014 1359 1368
5. M.F. Marmor, U. Kellner, T.Y.Y. Lai, J.S. Lyons, and W.F. Mieler Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy Ophthalmology 118 2 2011 415 422
6. J.D. Robinson, S.M. Lupkiewicz, L. Palenik, L.M. Lopez, and M. Ariet Determination of ideal body weight for drug dosage calculations Am J Hosp Pharm 40 6 1983 1016 1019
7. J.S. Lyons, and M.L. Severns Detection of early hydroxychloroquine retinal toxicity enhanced by ring ratio analysis of multifocal electroretinography Am J Ophthalmol 143 5 2007 801 809
8. D.S. Borkar, M.E. Lacouture, and S. Basti Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review Support Care Cancer 21 4 2013 1167 1174
9. D. Mahalingam, M. Mita, J. Sarantopoulos, and et al. Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors Autophagy 10 8 2014 1403 1414
10. R. Rangwala, Y.C. Chang, J. Hu, and et al. Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma Autophagy 10 8 2014 1391 1402
11. R. Rangwala, R. Leone, Y.C. Chang, and et al. Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma Autophagy 10 8 2014 1369 1379
12. R.B. Melles, and M.F. Marmor Pericentral retinopathy and racial differences in hydroxychloroquine toxicity Ophthalmology 122 1 2015 110 116